Atlas Trials

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Clinical trial NCT03258593 · COMPLETED

Trial details

NCT number
NCT03258593
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Urinary Bladder Neoplasms
Start date
2018-06-07
Primary completion
2022-08-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.